Pathophysiological Detection of Alpha-Fetoprotein in Iraqi Women with Polycystic Ovarian Syndrome

Main Article Content

Hajras Shaker Saleh
Iqbal A. AlRufaei
Enass Saleh Jawad

Keywords

Alpha-Fetoprotein, Polycystic Ovary Syndrome, Diagnostic, Iraqi women

Abstract

Polycystic ovary syndrome (PCOS), is one of the most common endocrinpathies in premenopausal women, which has been reclassified as a reproductive and metabolism disorder after the recognition of the important role of insulin resistance in the pathophysiology of the syndrome. Current surveillance strategy for patients with polycystic ovary syndrome at risk of nonalcoholic fatty liver disease
development is unsatisfactory. We aimed to investigate the diagnostic accuracy of alpha-fetoprotein (AFP). Moreover, existing data support that androgen excess, which existing data support that androgen excess, which is the main feature of PCOS and is interrelated to insulin resistance, may be an additional contributing factor to the development of non-alcoholic fatty liver disease (NAFLD).
The biomarker (AFP) was investigated in group of PCOS women (75) and group control (50). AFP showed higher in patients with PCOS (80 ± 0.22) compared to control group (0.67 ± 0.19) at p. value < 0.05. The results also showed a significant increase of AFP in PCOS women than control in all BMI categories with except normal weight was not scored significant difference at p. value < 0.05. The serum AFP levels estimated relationship between fatty liver disease and PCOS can effectively improve the diagnostic performance of PCOS, providing a new indicator that is simple, economical and pervasive for clinic.

Abstract 178 | pdf Downloads 153

References

1. Alselawi, A. H., AlRufaei, I. A., & Abbas, H. J. (2022). Evaluation of Betatrophin Hormone and Alpha-Fetoprotein Levels in Gestational and
Type 2 Diabetic Pregnant Women in Basrah Province. HIV Nursing, 22(2), 3102-3106.
2. Babalı A, Cakal E, Purnak T, Bıyıkoğlu I, Cakal B, Yüksel O, Köklü S. Serum α-fetoprotein levels in liver steatosis. Hepatol Int. 2009;3:551–555.
3. Barber TM, Franks S. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. Expert Rev
Endocrinol Metab. 2013;8(5):427-429.
4. Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, et al. Nonalcoholic
fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47:412–417.
5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty
liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the
American Gastroenterological Association. Hepatology. 2012;55:2005–2023.
6. Farrell, G. C., Wong, V. W. S., & Chitturi, S. (2013). NAFLD in Asia—as common and important as in the West. Nature reviews Gastroenterology & hepatology, 10(5), 307-318.
7. Gabant P, Forrester L, Nichols J, et al. Alphafetoprotein, the major fetal serum protein, is not essential for embryonic development but is
required for female fertility. Proc Natl Acad Sci USA. 2002; 99: 12865–12870.
8. Jones H, Sprung VS, Pugh CJ, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic
steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(10):3709–3716. doi:10.1210/jc.2012-1382.
9. Kara M, Genc H, Tapan S, Meral C, Ercin CN, Erdal M, Dogru T. Alpha fetoprotein levels and its relationship with histopathological findings in
patients with non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2013;17:1536–1541.
10. Kim CY, Bo RK, Sang SL, et al. Clinical features of hepatitis B and C virus infections, with high afetoprotein levels but not hepatocellular
carcinoma. Medicine 2017;96:e5844.
11. Macut D, Bjekic-Macut J, Livadas S, et al. Nonalcoholic fatty liver disease in patients with polycystic ovary syndrome. Curr Pharm Des.
2018;24:4593-4597.
12. Ollila MM, Piltonen T, Puukka K, et al. Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome:
prospective cohort study. J Clin Endocrinol Metab. 2016;101:739-747.
13. Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a metaanalysis. Hepat Mon. 2014;14(11):e23235.
14. Sarkar M, Terrault N, Chan W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int.
2020;40(2):355–359. doi:10.1111/liv.14279.
15. Sharony R, Dayan D, Kidron D, Manor M, Berkovitz A, Biron-Shental T, Maymon R. Is the ratio of maternal serum to amniotic fluid AFP
superior to serum levels as a predictor of pregnancy complications? Arch Gynecol Obstet. 2016 Apr; 293(4):767-70.
16. Teede HJ, Joham AE, Paul E, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity (Silver Spring). 2013;21:1526-1532.
17. Trevisani F, Garuti F, Neri A. Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection. Seminars in Liver Disease. 2019; 39:
163–177.
18. Wang T, Zhang KH, Hu PP, et al. Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFPelevated liver diseases. Oncotarget 2017.
19. Wang, F., Niu, W. B., Kong, H. J., Guo, Y. H., and Sun, Y. P. (2017a). The role of AMH and its receptor SNP in the pathogenesis of PCOS. Mol
Cell Endocrinol, 439, 363-368.
20. Wong RJ, Ahmed A, Gish RG. Elevated alphafetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clinics in Liver Disease. 2015; 19: 309–323.
21. Zhang J, Bao Y, Zhou X, Zheng L. Polycystic ovary syndrome and mitochondrial dysfunction. Reprod Biol Endocrinol. 2019; 17(1):67.